AllPennyStocks.com EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’

RBC Capital said that even if EyePoint’s second Phase 3 study delivers positive results, questions would remain over whether the U.S. Food and Drug Administration would approve the treatment based on a single trial.

Other Penny Stock Movers

A $1 Billion Crypto Deal Sends This Microcap Surging
This Microcap Just Pulled Core From One of Copper's Last Frontiers
Target Expansion and Geophysics Survey Trigger 18% Surge for Norwegian Base-Metal Project
Most Popular
{{ index + 1 }}


Back to Top